Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 144 participants.

Also called NCT01913847

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 144 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01913847
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01913847. Randomized; triple masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
Condition
Systolic Dysfunction
Intervention (Drug)
Sildenafil
Intervention (Drug)
Placebo
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct01913847
Content hash
540b6ea0fe3aab3eeabdcd3958b4979b6867d2f5171968316d2d19894590d246